
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics Corp is expected to see substantial growth, with anticipated procedure volumes increasing over 50% year-over-year in the second half of 2026, driven by successful commercial initiatives. The company demonstrated strong performance in its recent quarter with 58 new capital system placements, exceeding prior guidance and contributing to a 43% year-over-year sales increase to $83.3 million, surpassing both target and consensus projections. This robust demand, particularly within the benign prostatic hyperplasia (BPH) sector, along with expected increases in average selling prices, positions PROCEPT well for sustainable double-digit growth moving forward.
Bears say
PROCEPT BioRobotics Corp has announced fourth-quarter revenue that fell 19% below consensus expectations, coupled with a significant reduction in Fiscal Year 2026 sales guidance, indicating a troubling outlook for the company. The updated guidance projects sales of $390-410 million, which is 5% lower than market consensus, predominantly reflecting challenges in U.S. sales due to pressures on hospital profitability and reduced handpiece sales linked to the removal of bulk purchase discounts. This combination of disappointing financial performance and downward revisions has created significant volatility in the stock, leading to a negative sentiment among investors regarding the company's near-term prospects.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares